Deals In Depth: August 2020
Executive Summary
Biogen and Denali entered into a potential $2.15bn alliance for Denali’s DNL151 for Parkinson’s disease and other neurodegenerative diseases. Siemens Healthineers announced plans to acquire Varian Medical for $16.4bn. Financing reached $7.9bn in biopharma, $501m in device, and $639m in diagnostics.
You may also be interested in...
Deals In Depth: December 2020
Merck KGaA and Artios penned a global three-year strategic research collaboration to discover and develop multiple precision oncology drugs. The deal could be worth close to $7bn for four-year-old Artios. AstraZeneca announced a definitive agreement to acquire public rare disease drug developer Alexion for approximately $39bn. This was 2020’s largest M&A. Financing reached $28bn in biopharma, $879m in device, and $2.4bn in diagnostics.
Deals In Depth: November 2020
Biogen and Sage Therapeutics penned a potential $3.1bn global collaboration for Sage’s zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders, and SAGE-324 for essential tremor and other neurological disorders. In the month’s top M&A, Merck agreed to acquire privately held VelosBio for $2.75bn in cash. VelosBio is developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1. Financing reached $12.8bn in biopharma, $2.9bn in device, and $2bn in diagnostics.
Deals In Depth: October 2020
Two-year-old Insitro penned a potential $2.07bn collaboration with Bristol Myers Squibb focused on the discovery and development of therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The start-up will apply its ISH platform to create induced pluripotent stem cell-derived disease models. BMS also announced a definitive agreement to acquire MyoKardia for $13.1bn in cash. Financing reached $10.4bn in biopharma, $1.4bn in device, and $1.7bn in diagnostics.
Need a specific report? 1000+ reports available
Buy Reports